Merck, Pfizer launch phase III trial of ovarian cancer therapy
"There are limited treatment options for women with ovarian cancer, and the prognosis for women with platinum-resistant ovarian cancer is especially poor,” Chris Boshoff, vice president and head of early development, translational and immuno-oncology at Pfizer Oncology, said. "We have observed encouraging signs of early clinical activity of avelumab in patients with platinum-resistant or platinum-refractory ovarian cancer, and we hope to build on these results next year through a planned Phase III study of avelumab in combination with platinum therapy in patients with previously untreated ovarian cancer.”
JAVELIN Ovarian 200 Phase III is a randomized, open-label, parallel, multi-center, global study to assess overall survival rates of patients treated with avelumab. Test subjects include 550 patients from more than 190 locations across Asia, Europe and North America.
More information is available online at Pfizer's home page.
Organizations in this story
Pfizer 235 E 42nd St New York, NY 10017-5703